5 Stocks Pulling The Drugs Industry Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 15,482 as of Monday, July 15, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,893 issues advancing vs. 1,042 declining with 108 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.1%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.7%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biomarin Pharmaceutical is down $1.15 (-1.8%) to $63.66 on average volume. Thus far, 753,487 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $62.87-$64.97 after having opened the day at $64.97 as compared to the previous trading day's close of $64.81.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $8.4 billion and is part of the health care sector. Shares are up 22.6% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half